 | $5.75 Million in Sales Expected for Protagonist Therapeutics Inc (NASDAQ:PTGX) This Quarter
www.americanbankingnews.com - October 19 at 4:58 AM |
| Analysts Expect Protagonist Therapeutics Inc (NASDAQ:PTGX) Will Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - October 17 at 5:29 AM |
| Protagonist Therapeutics Inc (NASDAQ:PTGX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 16 at 1:32 AM |
| Protagonist Therapeutics Inc (NASDAQ:PTGX) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 15 at 6:11 AM |
 | The Protagonist Therapeutics (NASDAQ:PTGX) Share Price Is Down 45% So Some Shareholders Are Getting Worried
finance.yahoo.com - October 2 at 4:57 PM |
| Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
finance.yahoo.com - October 1 at 3:49 PM |
| Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
finance.yahoo.com - September 25 at 8:46 AM |
| Protagonist Therapeutics Inc (NASDAQ:PTGX) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - September 24 at 10:43 AM |
| Protagonist Therapeutics Reports Granting of Inducement Awards
finance.yahoo.com - September 4 at 5:15 PM |
| Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
finance.yahoo.com - September 3 at 5:42 PM |
| Does Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Salary Reflect Performance?
finance.yahoo.com - August 27 at 5:52 PM |
 | BRIEF-Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
www.msn.com - August 7 at 10:39 PM |
| Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 7 at 10:57 AM |
| Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 7 at 10:57 AM |
| Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
finance.yahoo.com - August 1 at 5:44 PM |
| Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - July 30 at 6:00 PM |
| Should You Be Worried About Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)?
finance.yahoo.com - July 11 at 5:41 PM |
| Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
finance.yahoo.com - June 23 at 4:49 PM |
| Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
finance.yahoo.com - June 17 at 11:20 AM |
 | New finance chief at Protagonist
seekingalpha.com - May 29 at 5:31 PM |
| Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
finance.yahoo.com - May 29 at 5:31 PM |
| Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 15 at 10:08 PM |
| Protagonist IBD candidate shows positive action in early-stage study; shares up 2%
seekingalpha.com - May 14 at 5:28 PM |
| Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
finance.yahoo.com - May 14 at 10:49 AM |
| Protagonist expands PTG-200 deal with Janssen; shares up 13%
seekingalpha.com - May 8 at 5:07 PM |
| Protagonist Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 8 at 10:32 AM |
 | Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
www.marketwatch.com - May 8 at 10:32 AM |
| What You Must Know About Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Beta Value
finance.yahoo.com - May 8 at 10:32 AM |
| Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 8 at 10:32 AM |
| Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019
finance.yahoo.com - May 7 at 10:27 AM |
| Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline
finance.yahoo.com - May 1 at 5:10 PM |
| Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9
finance.yahoo.com - April 1 at 12:06 PM |
 | Protagonist Therapeutics Inc.
www.barrons.com - March 15 at 4:56 PM |
| Protagonist Therapeutics, Inc.'s (PTGX) CEO Dinesh Patel on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 10:04 AM |
| Edited Transcript of PTGX earnings conference call or presentation 12-Mar-19 8:30pm GMT
finance.yahoo.com - March 13 at 10:04 AM |
| Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 12 at 9:04 PM |
| Protagonist Therapeutics: 4Q Earnings Snapshot
finance.yahoo.com - March 12 at 9:04 PM |
| Protagonist Therapeutics, Inc. (PTGX)
finance.yahoo.com - March 5 at 11:29 AM |
| Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 5 at 11:29 AM |
| Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
finance.yahoo.com - February 21 at 11:59 AM |
| Dosing underway in mid-stage study of Protagonist's PTG-300 in beta thalassemia
seekingalpha.com - January 9 at 9:48 AM |
| Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
finance.yahoo.com - January 9 at 9:48 AM |
| Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
www.marketwatch.com - January 7 at 9:29 AM |
| Protagonist finance chief to bid adieu
seekingalpha.com - January 1 at 8:57 AM |
| Who Has Been Buying Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares?
finance.yahoo.com - December 20 at 4:52 PM |
| Protagonist launches early-stage study of integrin antagonist for IBD
seekingalpha.com - December 13 at 8:58 AM |
| Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
finance.yahoo.com - December 13 at 8:58 AM |
| Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 5 at 9:27 AM |
| Protagonist down 15% after bailing on IBD candidate PTG-100
seekingalpha.com - November 28 at 4:43 PM |
 | Protagonist Therapeutics (PTGX) Announces New Development Candidate PN-10943 for the Treatment of IBD
www.streetinsider.com - November 28 at 9:32 AM |
